Iconix Pharmaceuticals Announces Scios Study

Iconix Pharmaceuticals announced that it has completed a study for Scios, a biopharmaceutical company focused on developing leading-edge treatments for cardiovascular disease, inflammatory disease and cancer. Under the terms of the agreement, Scios provided Iconix with tissue samples from experiments, and Iconix used its DrugMatrix and DrugSignature technologies to generate a detailed understanding of the compounds' biological properties.

()a href="http://biz.yahoo.com/prnews/050602/sfth042.html?.v=14" target="_blank">Yahoo News